Pregabalin for Opiate Withdrawal Syndrome

• Status: Completed
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

It is a single blind randomized symptom triggered study to assess efficacy and safety of pregablin combined with the symptom triggered treatment for opiate withdrawal syndrome vs. clonidne with the same with the symptom triggered treatment for opiate withdrawal syndrome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Petersburg Bekhterev Research Psychoneurological Institute
• Treatments: Antidiarrheals; Clonidine; Ketorolac; Ketorolac Tromethamine; Loperamide; Metoclopramide; Phenazepam; Pregabalin

Criteria

Inclusion Criteria:

• Opioid Use Disorders; Opioid Withdrawal Syndrome

Exclusion Criteria:

• Severe psychiatric and somatic disorders, other Substance Use Disorders (except tobacco)